7Baggers
 Canaccord Genuity reaffirms Buy rating on Annovis Bio stock  Investing.com Tue, 30 Sep 2025 12:19:02 GMT
 Published on: 2025-09-30 05:49:23  newser.com Tue, 30 Sep 2025 10:49:23 GMT
 Published on: 2025-09-28 12:29:05  newser.com Sun, 28 Sep 2025 17:29:05 GMT
 Annovis Bio names Mark Guerin as new chief financial officer By Investing.com  Investing.com Nigeria Fri, 26 Sep 2025 09:57:24 GMT
 Annovis Bio appoints Guerin as Chief Financial Officer  TipRanks Thu, 25 Sep 2025 11:52:46 GMT
 Annovis Bio names Mark Guerin as new chief financial officer  Investing.com Thu, 25 Sep 2025 11:44:27 GMT
 Annovis Appoints Mark Guerin as Chief Financial Officer  GlobeNewswire Thu, 25 Sep 2025 11:32:18 GMT
 annovis bio, inc. appoints mark guerin as chief financial officer  MarketScreener Thu, 25 Sep 2025 11:30:00 GMT
 parkinson's disease pipeline analysis, 2025 by delveinsight |  openPR.com Mon, 01 Sep 2025 17:48:06 GMT
 published on: 2025-08-30 15:09:55  Newser Sat, 30 Aug 2025 20:09:55 GMT
 annovis (anvs) secures patent coverage for both forms of buntanetap  Yahoo Finance Fri, 29 Aug 2025 07:00:00 GMT
 published on: 2025-08-28 02:44:49  Newser Thu, 28 Aug 2025 07:44:49 GMT

Annovis Bio, Inc
(NYSE:ANVS) 

ANVS stock logo

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chron...

Founded: 2008
Full Time Employees: 2
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends